FEMSelect, a company focused on pelvic organ prolapse (POP) treatment, has closed an oversubscribed Series B equity financing round to support commercial growth, leadership changes, and global expansion. The financing was led by existing investors New Age Ventures and Triventures, with participation from Robin Hood Ventures and RAD Biomed. New investors Nordwand Capital, Avea Ventures, and Terra Verde Comp also joined the round. The company did not disclose the specific amount raised.
“With participation from long-time and new investors, this influx of capital marks a major leap forward in our mission to redefine care for millions of underserved women worldwide,” said Renee Selman, Executive Chairwoman of the Board. “With a strengthened leadership team, expanded financial firepower, and a powerful product pipeline, FEMSelect is poised to accelerate growth and lead the way in transformative women’s health solutions.”
As part of its strategic advancement, FEMSelect has appointed Sasha Schrode as Chief Executive Officer. Schrode previously led Serpex Medical through to acquisition and brings experience in healthcare innovation and growth.
“FEMSelect has the power to transform women’s healthcare, and I’m thrilled to help bring this breakthrough to millions worldwide,” said Schrode. “Unlike traditional surgery—which often involves extensive dissection, longer recovery, and higher risk—the EnPlace procedure is minimally invasive, requires no dissection, and allows most women to go home the same day and resume their lives quickly.”
The company also announced the appointment of Debbie Garner as President, who will lead expansion efforts in the United States and internationally. Additionally, Rakesh Tailor, CEO of Contura International who previously led the development of Bulkamid and its sale to Axonics in 2021, has joined FEMSelect’s Board of Directors.
As part of its growth strategy, FEMSelect is relocating its headquarters from Israel to the United States to be closer to its largest market and enhance opportunities for strategic partnerships.
The company’s EnPlace technology offers a minimally invasive approach to treating pelvic organ prolapse, a condition that affects millions of women worldwide. Traditional surgical treatments often involve extensive recovery times and higher complication risks, while FEMSelect’s approach aims to provide a less invasive alternative.
